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epithelial tumorcells thatunderwenta tran-
sient dedifferentiation associated with
EMT rather than cancer stem cells that
pre-exist as a subpopulationof the primary
tumor. YB-1 gain or loss of translational
control could potentially be involved in
the regulation of both EMT and MET,
respectively.
These studies raise the question: is YB-1
a target for therapeutic intervention in
metastasis? As the authors point out,
direct targeting of YB-1 might prove to be
futile or even counterproductive since
YB-1 could be an important factor in
keeping cells dormant after they metasta-
size.
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A recent study published in Nature Medicine reports that low-dose treatment with RGD-mimetic integrin
inhibitors may paradoxically enhance angiogenesis and tumor growth. This work implies that delivery of
these agents should be redesigned in order to avoid nanomolar plasma concentrations and to improve their
efficacy to treat human cancers.Integrins mediate cell-cell and cell-matrix
interactions to ‘‘integrate’’ extracellular
cues with intracellular signaling pathways
and to promote a wide array of biological
responses. During development, tissue
remodeling, and in various disease condi-
tions, integrin-mediated cell migration/
invasion occurs via transient binding and
release of the extracellular matrix (ECM).
Thus, local microenvironments containing
substrate and soluble protein fragments
provide situational cues to integrins which
guide cell behavior. Several integrins,
including avb3 and avb5, recognize the
arginine-glycine-aspartic acid (RGD) se-
quence shared by a number of extra-
cellular matrix ligands. Accordingly, RGD-
mimetic peptides or small molecules bind
to these integrins on the surface of cells to
block specific av integrin-mediated sig-
naling pathways and act as anticancer
and antiangiogenic agents.
Reynolds and colleagues recently re-
ported in Nature Medicine that low nano-
molar concentrations of RGD mimeticsmay actually stimulate tumor growth and
angiogenesis (Reynolds et al., 2009).
These conclusions were drawn from
examination of B16F0 melanoma or LLC
lung carcinoma cells grown on the flanks
of syngeneic C57BL6 mice treated sys-
temically with a cyclic RGD peptide (cilen-
gitide) or a small molecule RGD mimetic
(S 36578). Since the RGD mimetics did
not increase tumor growth or vasculariza-
tion in integrin b3/b5 double knockout
mice, the authors concluded that low
doses of integrin antagonists promoted
tumor growth by acting on host endothe-
lial cells. While these findings may seem
surprising, several independent groups
reported in the early 1990s that nanomo-
lar concentrations of soluble ECM pro-
teins could induce chemotaxis (Aznavoor-
ian et al., 1990) and that the chemotaxis
induced specifically by RGD-containing
fibronectin fragments could be overcome
by millimolar concentrations of RGD-con-
taining peptides (Odekon et al., 1991). As
a rationale for their experiments, Rey-Cancer Cnolds et al. also pointed to work by Legler
and coworkers who found that cyclic
RGD-peptides have a biphasic effect on
avb3, with an antagonistic phase at high
concentrations and an agonistic phase
at low concentrations (Legler et al.,
2001). Thus, it has been known for years
that low concentrations of soluble antag-
onists will agonize or ‘‘superactivate’’
(Legler et al., 2001) integrins (Figure 1).
Nonetheless, in their new study, Reynolds
et al. have extended these previous find-
ings to confirm that integrin activation by
low-dose antagonists does occur in
endothelial cells and may be relevant for
angiogenesis among subcutaneously
growing tumors.
The authors commented in the paper
that integrin antagonism as an antiangio-
genic therapy has been largely unsuc-
cessful in man and that any observed
efficacy is probably due to direct ac-
tion on tumor cells. While it is generally
true that many antiangiogenic strategies
for cancers have performed belowell 15, May 5, 2009 ª2009 Elsevier Inc. 359
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PreviewsFigure 1. Balance of Integrin Activation Regulates Cell Movement between Tissue Microenvironments
Activity of av integrins can be modulated by binding to soluble integrin ligand, leading to changes in cell behavior. High doses of RGD-mimetic integrin inhibitors
act as integrin antagonists and antiangiogenic agents, whereas low doses of the same drugs paradoxically activate av integrins to promote migration, invasion,
and angiogenesis. The signals produced by endogenous RGD-containing ECM proteins and soluble fragments can thereby be outcompeted by exposure to mM
doses of RGD-mimetic drugs.expectation, cilengitide as a single therapy
has shown efficacy and antiangiogenic
activity in glioma patients (Nabors et al.,
2007) and achieved stable disease in
late-stage glioblastoma, a significant
improvement over existing treatment
strategies. In addition, cilengitide in
combination with chemotherapies or
other agents is currently being tested in
ongoing clinical trials. Reynolds et al.
further show that antibody-mediated
blockade of VEGFR2 function (using
DC101) suppresses the ability of nanomo-
lar concentrations of integrin antagonists
to promote angiogenesis and tumor
growth. Based on these findings, the
authors speculate that the antiangiogenic
efficacy of integrin antagonism could be
improved by combination with VEGFR
antagonism. While anti-VEGF (i.e., bevaci-
zumab) as a single therapy produces little
or no efficacy in man, approaches that
target the VEGF pathway serve to360 Cancer Cell 15, May 5, 2009 ª2009 Elsenormalize vasculature, thereby facilitating
drug delivery to the tumor (Fukumura and
Jain, 2007; Greenberg et al., 2008). Future
studies must optimize whether anti-angio-
genic strategies should be employed as
single or combination therapies to treat
specific cancers.
Mechanistically, Reynolds et al. report
that low doses of integrin antagonists
induce angiogenesis by enhancing VEGF-
stimulated migration of endothelial cells,
which depends on their capacity to
promote Rab4A-mediated recycling of
VEGFR2 and avb3 integrin. Although
blood vessels in normal tissues do not
express avb3, tumor-associated vessels
express high levels of this integrin. Thus,
the use of cultured endothelial cells to
study recycling kinetics of VEGFR2 or
avb3 may not be entirely representative
of the in vivo situation. Nevertheless, the
authors point out that cilengitide has
recently been shown to promote tumorvier Inc.cell invasion by altering recycling kinetics
of integrin a5b1 and EGFR (Caswell et al.,
2008). Thus, integrin antagonism may
modulate cell migration in general by
promoting integrin and growth factor re-
cycling in tumor cells and endothelial cells
alike (Figure 1). Future work is required to
understand how various other cell types
involved with tumor progression (such as
fibroblasts or smooth muscle cells) may
respond to low or high doses of integrin
antagonists.
To directly assess the impact of integrin
antagonism on angiogenic sprouting, the
authors used an aortic ring assay to
demonstrate that low doses of RGD
mimetics enhance endothelial sprouting
into a 3D extracellular matrix, independent
of any effects on tumor cells. This model
yielded an interesting finding: exposure
to low doses of the integrin antagonist
impaired the antiangiogenic response to
subsequently applied higher doses. The
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injections resulting in fluctuations be-
tween high and low concentrations of in-
tegrin antagonists might undermine the
efficacy of such inhibitors. However, this
hypothesis needs to be tested using
more relevant preclinical models, as the
ex vivo sprouting of aortic ring explants
only poorly approximates the complicated
pharmacokinetics or microenvironment
associated with systemic dosing of
patients with such drugs.
It should be pointed out that Reynolds
et al. used an osmotic minipump to
deliver constant low nM doses of the
drug in order to maintain its low steady-
state level in mice with flank tumors. It
remains to be seen how chronic low-
dose administration of integrin antago-
nists is relevant to the much higher
average concentrations of the same
drugs which have been reported to
produce clinical activity in man (Nabors
et al., 2007). It is also not clear how
plasma concentrations of integrin antag-
onists correlate to the varying concen-
trations within different microenviron-
ments of a tumor. Furthermore, there
are endogenous soluble integrin ligands
such as tumstatin, endostatin, or angios-tatin that may function cooperatively with
RGD mimetics, making the effective
concentration of soluble integrin antago-
nists in vivo difficult to interpret. As typi-
cally used for human trials, bolus admin-
istration of integrin antagonists may
provide a better clinical correlate than
the experimental conditions as defined
by Reynolds et al. The use of such inhib-
itors might also be better applied to
either spontaneous tumors or those that
are orthotopically implanted, since pre-
vious mouse studies have revealed that
cilengitide blocks angiogenesis and
glioma progression in the orthotopic
environment of the brain but is ineffective
on these cells growing in the same
animals as a subcutaneous xenograft
(MacDonald et al., 2001). Although RGD
mimetics might be particularly suited for
the brain microenvironment, these agents
may also provide significant benefit in
other tumors depending on local tissue
cues. Regardless, the host response to
the tumor microenvironment is currently
a hot topic in cancer research, and
integrin signaling plays a key role in
determination of cell fate when exposed
to different extracellular matrix compo-
nents.Cancer CREFERENCES
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